BBHC
ZYNE

Brown Brothers Harriman & Co’s Zynerba Pharmaceuticals, Inc ZYNE Stock Holding History

Brown Brothers Harriman & Co’s Portfolio ZYNE Stock Details ZYNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-2,085
Closed -$26K – 1184
2017
Q4 		$26K Buy
+2,085
New +$23.9K ﹤0.01% 612

Other funds holding ZYNE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FTIOP
Fiduciary Trust International of Pennsylvania Radnor, Pennsylvania $2.14B AUM 3.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ARTA
A.R.T. Advisors New York $1.79M AUM 57.47% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $103B AUM 28.65% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Brown Brothers Harriman & Co's ZYNE Position: Q1 2018 in Review

Brown Brothers Harriman & Co sold out of Zynerba Pharmaceuticals, Inc (ZYNE) in Q1 2018, closing a stake of 2,085 shares — an estimated $26K sold.

Brown Brothers Harriman & Co first reported a position in ZYNE in Q4 2017 and held it in 1 quarter. The position peaked at $26K in Q4 2017. 61 funds tracked by Wall St. Rank hold ZYNE as of Q1 2018.

  • Brown Brothers Harriman & Co reported no remaining Zynerba Pharmaceuticals, Inc position as of Q1 2018 after selling out during the quarter.
  • Brown Brothers Harriman & Co sold 2,085 Zynerba Pharmaceuticals, Inc shares in Q1 2018, an estimated $26K.
  • Brown Brothers Harriman & Co first reported a position in Zynerba Pharmaceuticals, Inc in Q4 2017 and held it in 1 quarter.
  • Brown Brothers Harriman & Co's Zynerba Pharmaceuticals, Inc position peaked at $26K in Q4 2017.
  • 61 funds tracked by Wall St. Rank held Zynerba Pharmaceuticals, Inc as of Q1 2018.

Based on Brown Brothers Harriman & Co's 13F filing for Q1 2018, filed 14 May 2018.